Cargando…

Epigenetic Changes of EGFR play an important role in BRAF inhibitor Resistant Cutaneous Melanomas

BRAF mutations are frequent in cutaneous melanomas and BRAF inhibitors(BRAFi) have shown remarkable clinical efficacy in BRAF mutant melanoma patients. However, acquired drug resistance can occur rapidly and tumor(s) often progress thereafter. Various mechanisms of BRAFi resistance have recently bee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jinhua, Huang, Sharon K., Marzese, Diego M., Hsu, Sandy C., Kawas, Neal P., Chong, Kelly K., Long, Georgina V., Menzies, Alexander M., Scolyer, Richard A., Izraely, Sivan, Sagi-Assif, Orit, Witz, Isaac P., Hoon, Dave S.B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307785/ https://www.ncbi.nlm.nih.gov/pubmed/25243790 http://dx.doi.org/10.1038/jid.2014.418

Ejemplares similares

The CASC15 long intergenic non-coding RNA locus is involved in melanoma progression and phenotype-switching
por: Lessard, Laurent, et al.
Publicado: (2015)

ANGPTL4 promotes the progression of cutaneous melanoma to brain metastasis
por: Izraely, Sivan, et al.
Publicado: (2017)

CCR4 is a determinant of melanoma brain metastasis
por: Klein, Anat, et al.
Publicado: (2017)

Heterogeneity in the Metastatic Microenvironment: JunB-Expressing Microglia Cells as Potential Drivers of Melanoma Brain Metastasis Progression
por: Adir, Orit, et al.
Publicado: (2023)

Inter-Tumor Heterogeneity—Melanomas Respond Differently to GM-CSF-Mediated Activation
por: Moshe, Adi, et al.
Publicado: (2020)

Cystatin C takes part in melanoma-microglia cross-talk: possible implications for brain metastasis
por: Moshe, Adi, et al.
Publicado: (2018)

The melanoma brain metastatic microenvironment: aldolase C partakes in shaping the malignant phenotype of melanoma cells – a case of inter‐tumor heterogeneity
por: Izraely, Sivan, et al.
Publicado: (2020)

The Challenge of Classifying Metastatic Cell Properties by Molecular Profiling Exemplified with Cutaneous Melanoma Cells and Their Cerebral Metastasis from Patient Derived Mouse Xenografts
por: Neuditschko, Benjamin, et al.
Publicado: (2020)

Site‐specific metastasis: A cooperation between cancer cells and the metastatic microenvironment
por: Izraely, Sivan, et al.
Publicado: (2020)

The Vicious Cycle of Melanoma-Microglia Crosstalk: Inter-Melanoma Variations in the Brain-Metastasis-Promoting IL-6/JAK/STAT3 Signaling Pathway
por: Izraely, Sivan, et al.
Publicado: (2023)

Regeneration Enhances Metastasis: A Novel Role for Neurovascular Signaling in Promoting Melanoma Brain Metastasis
por: Prakash, Roshini, et al.
Publicado: (2019)

PHOX2B is a suppressor of neuroblastoma metastasis
por: Naftali, Osnat, et al.
Publicado: (2016)

Hexokinase 2 is a determinant of neuroblastoma metastasis
por: Edry Botzer, Liat, et al.
Publicado: (2016)

Multi-platform genome-wide analysis of melanoma progression to brain metastasis
por: Marzese, Diego M., et al.
Publicado: (2014)

Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis
por: Ramos, Romela Irene, et al.
Publicado: (2020)

Cancer drug resistance induced by EMT: novel therapeutic strategies
por: De Las Rivas, Javier, et al.
Publicado: (2021)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
por: Pupo, Gulietta M., et al.
Publicado: (2017)

Intra-patient heterogeneity of BRAF mutation status: fact or fiction?
por: Menzies, A M, et al.
Publicado: (2014)

Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors
por: Ziemys, Arturas, et al.
Publicado: (2020)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Genome-wide chromatin accessibility, DNA methylation and gene expression analysis of histone deacetylase inhibition in triple-negative breast cancer
por: Bustos, Matias A., et al.
Publicado: (2017)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
por: Notarangelo, Tiziana, et al.
Publicado: (2017)

LY6S, a New IFN-Inducible Human Member of the Ly6a Subfamily Expressed by Spleen Cells and Associated with Inflammation and Viral Resistance
por: Shmerling, Moriya, et al.
Publicado: (2022)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

The RhoJ-BAD signaling network: An Achilles’ heel for BRAF mutant melanomas
por: Ruiz, Rolando, et al.
Publicado: (2017)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

The tumor microenvironment: the involvement of the selectin-selectin-ligand axis in tumor-endothelium interactions
por: Witz, Isaac P
Publicado: (2006)

The Tumor Microenvironment: The Making of a Paradigm
por: Witz, Isaac P.
Publicado: (2009)

EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAF(V600E) mutation: a case report and review of literature
por: Zeng, Ran, et al.
Publicado: (2021)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/β-Catenin Signaling
por: Chien, Andy J., et al.
Publicado: (2014)

Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants
por: Wegert, Jenny, et al.
Publicado: (2018)

Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
por: Bayrak, Omer, et al.
Publicado: (2014)

Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer
por: Schaufler, Diana, et al.
Publicado: (2021)

Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
por: Wang, Minyu, et al.
Publicado: (2022)

An amino-terminal BRAF deletion accounting for acquired resistance to RAF/EGFR inhibition in colorectal cancer
por: Tung, Jack K., et al.
Publicado: (2020)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma
por: Chan, Xian Yang, et al.
Publicado: (2017)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
por: Carlino, M S, et al.
Publicado: (2014)

Late immune and haemopoietic functions in plasmacytoma-bearing mice cured by melphalan.
por: Sagi, O., et al.
Publicado: (1988)

Cannot write session to /tmp/vufind_sessions/sess_hejkc8epa3931va1fchb5o62n4